Routine blood tests are increasingly detecting elevated liver enzymes, which may signal liver stress or damage. While mild ...

Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and strong tolerability.

Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis ...

Altimmune said on Friday its experimental liver disease drug led to weight loss and improved markers for scarring and health of the organ based on non-invasive tests after 48 weeks of treatment in a ...

Altimmune (ALT) stock is in focus as the company announces data from a mid-stage trial for its MASH therapy pemvidutide ...

In 'Sick Nation', Karan Sarin offers a proactive, preventative protocol for metabolic health—designed to detect and address insulin resistance in Indians.

Participants receiving pemvidutide 1.2 mg and 1.8 mg achieved weight loss of 4.5% and 7.5%, respectively, vs. 0.2% of placebo-treated participants (p<0.0001, both doses), with no plateauing at 48 ...

Shares of Altimmune rose on positive trial results for its treatment for metabolic dysfunction-associated steatohepatitis, or MASH, a liver disease. The stock climbed 7.5% to $5.43 in premarket ...

On December 19, 2025, Altimmune reported positive 48-week topline results from its IMPACT Phase 2b trial of pemvidutide in patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, showing ...

A meta-analysis finds that mobile health tools, such as apps and text messages, support weight management and improve liver ...

It's been a natural remedy for liver damage for more than 2,000 years and was the fourth highest selling supplement at health ...